TABLE 5.
Accuracy of susceptibility testing of mutant HIV-1 recombinant viruses toward PR, RT, IN, and entry inhibitors
| Recombined region | Mutation(s)a | Inhibitor | Fold change in IC50b | Referencec |
|---|---|---|---|---|
| gag-PR | I13V, I15V, K20R, E35D, M36I, I54V, L63P, I64V, A71V, N88D, L90M* | NFV | 7.75 | 25 |
| PR | I13V, I15V, K20R, E35D, M36I, I54V, L63P, I64V, A71V, N88D, L90M* | NFV | 9.46 | 25 |
| RT | Q151M | AZT | 1.60 | 34 |
| ABC | 2.76 | 34 | ||
| TDF | 0.85 | 44 | ||
| K70R | AZT | 1.71 | 30 | |
| ABC | 0.95 | 30 | ||
| TDF | 0.85 | 55 | ||
| K65R | AZT | 1.13 | 40 | |
| ABC | 5.17 | 40 | ||
| TDF | 2.41 | 44 | ||
| A62V, S68G, V75I, F77L, F116Y, Q151M | AZT | 79.07 | 29 | |
| ABC | 11.66 | 29 | ||
| TDF | 2.11 | 29 | ||
| M41L, D67N, K70R, V179I, M184V, Y188L, T215Y** | AZT | 10.10 | 20 | |
| ABC | 23.26 | 20 | ||
| TDF | 2.02 | 31 | ||
| 3TC | >1,100 | 20 | ||
| EFV | 111.80 | 25 | ||
| NVP | >100 | 25 | ||
| IN | T66I | RAL | 0.98 | 18 |
| EVG | 4.29 | 18 | ||
| env | gp41, D36G, V38M | ENF | 5.88 | 22 |
| AMD3100 | 1.15 | 39 | ||
| Env-He | AMD3100 | No inhibition | 35 | |
| MVC | No inhibition | 35 | ||
| Env-He-gp41 V38M | ENF | 2.56 | 39 | |
| Env-BaL | AMD3100 | No inhibition | 35 | |
| Env-BaL-gp41 V38M | ENF | 4.19 | 39 |
a
Mutations were generated by site-directed mutagenesis, except for the two strains that originated from a clonal sequence from a patient sample (subtype B) (*) and one strain that originated from a clonal sequence from another patient sample (subtype C) (**).
b
Relative to the wild-type recombinant virus recombined in the respective region (gag-PR-p83-2, PR-p83-2, IN-p83-2, env-p83-10-gp41-D36G, env-He, or env-BaL) (triplicate experiment).
c
Published reference in which comparable results were obtained.